Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues

The leadership transition coincides with the release of the company's half-year financial report for 2026. Bloomberg and Seeking Alpha note that Sanofi outperformed second-quarter expectations, driven largely by a surge in sales for the blockbuster skin drug Dupixent. This performance led the firm to raise its outlook, reinforcing the financial significance of its existing product portfolio.

Despite the positive sales data, shares experienced a decline. Reuters and The Wall Street Journal identify pipeline setbacks as a primary driver for investor apprehension, pointing to a reliance on Dupixent and difficulties in filling the drug development queue. Fierce Biotech characterizes the internal process as a clinical clearout, highlighting the friction between immediate growth and long-term research sustainability.

While the company remains in a growth phase regarding its current sales trajectory, the strategy moving forward is centered on Garijo’s effort to overhaul R&D operations. Future market performance will depend on the effectiveness of the pipeline cleanup and the success of the targeted expansion efforts into China, as coverage does not yet specify which clinical programs face potential termination.